Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

such as Zepbound and Mounjaro, over the last year. Eli Lilly on Thursday reported mixed results for the fourth quarter as ...

The names at the forefront of weight loss drugs are Eli Lilly, the U.S. manufacturer of Mounjaro and Zepbound; and Novo Nordisk, the Danish maker of Ozempic, Saxenda, and Wegovy. However ...

At the heart of Eli Lilly's growth story is its robust portfolio of GLP-1 drugs. Mounjaro and Zepbound have shown impressive ... an oral GLP-1 receptor agonist that has shown promising weight loss ...

It's also working on another, even more powerful weight-loss shot. While Ozempic mimics one hunger-relieving hormone, and Mounjaro mimics two, Eli Lilly is working on what's called a "triple ...

Patrik Jonsson is an executive vice president at Eli Lilly ... Jonsson has run Lilly Diabetes and Obesity, which means he oversees everything from insulin shots to the newer, high-demand drugs now ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly(NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by far ...